Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
May 02, 2024 16:05 ET
|
Biomea Fusion, Inc.
Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes patients, displaying durable improved glycemic control while off therapy for 22 weeks,...
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 01, 2024 16:10 ET
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and...
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 01, 2024 16:10 ET
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and...
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
April 01, 2024 09:02 ET
|
Biomea Fusion, Inc.
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes The first two type 1 diabetes patients enrolled in...
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
April 01, 2024 09:00 ET
|
Biomea Fusion, Inc.
In 2023, reported Phase 2 data (COVALENT-111) in type 2 diabetes patients supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy,...
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
March 06, 2024 03:04 ET
|
Biomea Fusion, Inc.
Three Clinical Data Sets from the Dose Escalation Phase of COVALENT-111 to be Presented at the 17th Annual ATTD Conference Highlighting BMF-219’s Novel Mechanism of Action in Patients with Type 2...
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 01, 2024 16:16 ET
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and...
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
January 09, 2024 11:02 ET
|
Biomea Fusion, Inc.
Expansion portion of Phase II COVALENT-111 study readout in 216 patients with type 2 diabetes expected in 2024.Open label portion of Phase II COVALENT-112 study readout in 40 patients with type 1...
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
January 08, 2024 09:00 ET
|
Biomea Fusion, Inc.
The clinical study, COVALENT-112, has initiated enrollment of adults living with type 1 diabetes in the US and Canada.Eligible patients include those who have been diagnosed with type 1 diabetes for...
Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 16:05 ET
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel...